Filling and packing machines for pharmaceutical products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

OPTIMA pharma

For uncompromising pharmaceutical applications

When it comes to manufacturing pharmaceutical products, there can simply be no compromises. Optima Pharma develops and builds filling, sealing and process equipment in accordance with this guiding principle. Its technology is used to process blood plasma products, vaccines, oncology and biotech products in prefilled syringes, vials, IV bottles and carpules. Sterile and non-sterile liquid pharmaceuticals, diagnostic agents and their specific product characteristics combined with special customer requirements set the standard for what technology is implemented.

The core of the machines consists of dosing and sealing systems, complemented by additional functions and process equipment. Washing machines, sterilization tunnels, containment and freeze drying systems, automated loading/unloading and robotic handling complete the comprehensive product range. Optima Pharma specializes in flexibly carrying out complex projects – on time, and on budget. The division’s extensive certifications, the quality of its engineering and the rapid response times of its professional service departments around the globe ensure outstanding long-term equipment effectiveness for customers.

OPTIMA pharma GmbH is a member of the OPTIMA packaging group GmbH with headquarters in Schwäbisch Hall. Other subsidiaries operate in the fields Consumer, Nonwovens and Life science. Founded in 1922, the family business employs a workforce of 1,800 at its three sites in Germany and 13 locations abroad.

Company name:  OPTIMA pharma GmbH

Website: www.optima-pharma.com

E-mail: info@optima-pharma.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here